Scientists have identified a protein that operates in tandem with a specific genetic mutation to spur lung cancer growth and could serve as a therapeutic target to treat the disease.
Mutations in the p53 gene are found in more than half of all cancers, but it remains difficult to effectively target the gene with drugs even decades after its discovery. Though previous research has shown that p53 acts as a tumor suppressor and initiates cancer cell death in its natural state, a new study suggests that gain-of-function (GOF) mutations -- a type of mutation where the changed gene has an added function -- turn p53 into an oncogene, causing cells to replicate uncontrollably and contribute to cancer development.
Recently published in Nature Communications, the researchers determined that mutant p53 genes are empowered by a specific protein, PLK3, to copy their genetic code and promote tumor cell proliferation through a process called transactivation.
Using preclinical models of lung cancer driven by p53 GOF mutations, the research team discovered that PLK3 activates an amino acid called serine 20 (S20), a cellular building block they found to play an important role in cancer cell replication.
By inhibiting PLK3 in GOF p53 mutant cells, they observed a decrease in the function of S20 along with overall reductions in transactivation and tumor cell formation.
"Our research indicates that GOF p53 exploits PLK3 to trigger its transactivation capability and exert oncogenic functions, raising the possibility of targeting p53-driven cancer cells using PLK3 inhibitors," said the senior author.
The team will continue to explore the potential for PLK3 inhibitors to be effective drugs in the treatment of lung cancer and potentially other forms of disease with the same genetic mutation.
https://www.masseycancercenter.org/news/Massey-scientists-identify-protein-that-could-serve-as-therapeutic-target-in-lung-cancer
https://www.nature.com/articles/s41467-021-20928-8
http://sciencemission.com/site/index.php?page=news&type=view&id=publications%2Fthe-oncogenicity-of&filter=22
Mutant p53 is enhanced by the recruitment of PLK3 in lung cancer
- 1,302 views
- Added
Edited
Latest News
Hyperactive platelets from…
By newseditor
Posted 19 May
Chromatin and RNA interacti…
By newseditor
Posted 18 May
Why patients with ARID1A mu…
By newseditor
Posted 18 May
Smuggling small molecule mo…
By newseditor
Posted 18 May
Men with gene mutations are…
By newseditor
Posted 17 May
Other Top Stories
Alternate splicing sequence determinants identified!
Read more
MicroRNAs regulating cholesterol and triglyceride homeostasis ident…
Read more
RNA Controls Poly-glutamine Protein Phase Transitions
Read more
Nuclear membrane repairs the 'dark matter' of DNA
Read more
Transmembrane protein sorting driven by membrane curvature
Read more
Protocols
Breast cancer-on-chip for p…
By newseditor
Posted 16 May
Methods for making and obse…
By newseditor
Posted 15 May
Mime-seq 2.0: a method to s…
By newseditor
Posted 13 May
Improved detection of DNA r…
By newseditor
Posted 09 May
Single-cell adhesive profil…
By newseditor
Posted 07 May
Publications
A microglial activation cas…
By newseditor
Posted 19 May
An age-progressive platelet…
By newseditor
Posted 19 May
Immunotherapy for colorecta…
By newseditor
Posted 18 May
Single-cell multiplex chrom…
By newseditor
Posted 18 May
Autophagy preferentially de…
By newseditor
Posted 18 May
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar